Targeting Hepatic Stellate Cells for the Prevention and Treatment of Liver Cirrhosis and Hepatocellular Carcinoma: Strategies and Clinical Translation
Pharmaceuticals · 31.03.2025 · 18 (4) · 507
DOI: 10.3390/ph18040507 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 31.03.2025. Verfasst von Hao Xiong und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Zhongshan Hospital, Shanghai Institute of Liver Diseases, Fudan University, Shanghai 200032, China. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 147 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Fund of Nature Science of P.R. China, Shanghai Pujiang Talent Program, National Fund of Nature Science of China.
Abstract (Originalsprache)
Hepatic stellate cells (HSC) are the major source of myofibroblasts (MFB) in fibrosis and cancer- associated fibroblasts (CAF) in both primary and metastatic liver cancer. Over the past few decades, there has been significant progress in understanding the cellular and molecular mechanisms by which liver fibrosis and HCC occur, as well as the key roles of HSC in their pathogenesis. HSC-targeted approaches using specific surface markers and receptors may enable the selective delivery of drugs, oligonucleotides, and therapeutic peptides that exert optimized anti-fibrotic and anti-HCC effects. Recent advances in omics, particularly single-cell sequencing and spatial transcriptomics, hold promise for identifying new HSC targets for diagnosing and treating liver fibrosis/cirrhosis and liver cancer.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology and Hepatology, Zhongshan Hospital, Shanghai Institute of Liver Diseases, Fudan University, Shanghai 200032, China.
- Department of Internal Medicine, Shanghai Medical College, Fu Dan University, Shanghai 200032, China.
ORCID-Profile: Jinsheng Guo
Förderung
- National Fund of Nature Science of P.R. China
- Shanghai Pujiang Talent Program
- National Fund of Nature Science of China
Zitieren
APA
Xiong, H., & Guo, J. (2025). Targeting Hepatic Stellate Cells for the Prevention and Treatment of Liver Cirrhosis and Hepatocellular Carcinoma: Strategies and Clinical Translation. Pharmaceuticals, 18(4), 507. https://doi.org/10.3390/ph18040507
Vancouver
Xiong H, Guo J. Targeting Hepatic Stellate Cells for the Prevention and Treatment of Liver Cirrhosis and Hepatocellular Carcinoma: Strategies and Clinical Translation. Pharmaceuticals. 2025;18(4):507. doi:10.3390/ph18040507
BibTeX
@article{Xiong2025,
author = {Xiong, Hao and Guo, Jinsheng},
title = {Targeting Hepatic Stellate Cells for the Prevention and Treatment of Liver Cirrhosis and Hepatocellular Carcinoma: Strategies and Clinical Translation},
journal = {Pharmaceuticals},
year = {2025},
volume = {18},
number = {4},
pages = {507},
doi = {10.3390/ph18040507}
}
EUVIMED